Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1998
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
LETTER TO EDITOR
Year : 2003  |  Volume : 51  |  Issue : 2  |  Page : 198-199

Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report.



Correspondence Address:
P Parmar


Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 12831159

Rights and PermissionsRights and Permissions

How to cite this article:
Parmar P, Salman A. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol 2003;51:198-9

How to cite this URL:
Parmar P, Salman A. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol [serial online] 2003 [cited 2019 Sep 22];51:198-9. Available from: http://www.ijo.in/text.asp?2003/51/2/198/14699

Dear Editor,

We read with interest the article by Mandal and associates[1] on the use of mitomycin-C (MMC) augmented trabeculectomy for the management of neovascular glaucoma (NVG). We have also found that while the use of MMC augmented trabeculectomy for NVG is fairly widespread, published studies regarding this procedure are scarce. However, we disagree that there are no published reports about this technique. We are aware of at least two studies involving use of MMC in trabeculectomy for NVG that appear in the literature. Hyung and Kim[2] studied MMC-augmented trabeculectomy in 24 eyes of 23 patients with NVG with a mean follow-up of 25.8 months (this article is indexed in MEDLINE). They found an average intraocular pressure (IOP) reduction of about 28.6 mmHg and a success rate of 71% at 1 month, which fell to 29% at 12 months. They conclude that this technique is successful in the treatment of NVG. Rao et al[3] studied anterior retinal cryoablation prior to MMC augmented trabeculectomy in management of NVG. Chronic open angle glaucoma, chronic uveitis, proliferative diabetic retinopathy and ischaemic central retinal vein occlusion were the main causes of NVG. Of the 13 eyes undergoing surgery, IOP was controlled in 12 with a mean IOP reduction of 20 mmHg.

In addition, a clarification is required regarding the number of eyes that received previous retinal ablation in the present study.[1] [Table 1] shows that 10 eyes (66.7%) received prior ablation while a look at [Table 2] shows that 13 eyes (86.7%) have received prior ablation.

 
  References Top

1.
Mandal AK, Majji AB, Mandal SP, Das T, Jalali S, Gothwal VK, et al. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol 2002;50:287-93.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.
Hyung SM, Kim SK. Mid-term effects of trabeculectomy with mitomycin-C in neovascular glaucoma patients. Korean J Ophthalmol 2001;15:98-106.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.
Rao VA, Salman A, Parmar P, Babu N. Anterior retinal cryoablation in the management of neovascular glaucoma. Proceedings of All India Ophthalmological Conference 200;217:19.  Back to cited text no. 3
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed2137    
    Printed83    
    Emailed0    
    PDF Downloaded162    
    Comments [Add]    

Recommend this journal